JP2013519645A5 - - Google Patents

Download PDF

Info

Publication number
JP2013519645A5
JP2013519645A5 JP2012552369A JP2012552369A JP2013519645A5 JP 2013519645 A5 JP2013519645 A5 JP 2013519645A5 JP 2012552369 A JP2012552369 A JP 2012552369A JP 2012552369 A JP2012552369 A JP 2012552369A JP 2013519645 A5 JP2013519645 A5 JP 2013519645A5
Authority
JP
Japan
Prior art keywords
methylbutyl
piperidinyl
dihydro
oxy
pentyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012552369A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013519645A (ja
JP5922587B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/051830 external-priority patent/WO2011098452A1/en
Publication of JP2013519645A publication Critical patent/JP2013519645A/ja
Publication of JP2013519645A5 publication Critical patent/JP2013519645A5/ja
Application granted granted Critical
Publication of JP5922587B2 publication Critical patent/JP5922587B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012552369A 2010-02-10 2011-02-08 6−アミノ−2−{[(1s)−1−メチルブチル]オキシ}−9−[5−(1−ピペリジニル)ペンチル]−7,9−ジヒドロ−8h−プリン−8−オンマレイン酸塩 Active JP5922587B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30301010P 2010-02-10 2010-02-10
US61/303,010 2010-02-10
PCT/EP2011/051830 WO2011098452A1 (en) 2010-02-10 2011-02-08 6-amino-2-{ [ (1s)-1-methylbutyl] oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8h-purin-8-one maleate

Publications (3)

Publication Number Publication Date
JP2013519645A JP2013519645A (ja) 2013-05-30
JP2013519645A5 true JP2013519645A5 (cg-RX-API-DMAC7.html) 2014-03-27
JP5922587B2 JP5922587B2 (ja) 2016-05-24

Family

ID=43836817

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012552369A Active JP5922587B2 (ja) 2010-02-10 2011-02-08 6−アミノ−2−{[(1s)−1−メチルブチル]オキシ}−9−[5−(1−ピペリジニル)ペンチル]−7,9−ジヒドロ−8h−プリン−8−オンマレイン酸塩

Country Status (23)

Country Link
US (1) US8703754B2 (cg-RX-API-DMAC7.html)
EP (1) EP2534149B1 (cg-RX-API-DMAC7.html)
JP (1) JP5922587B2 (cg-RX-API-DMAC7.html)
KR (1) KR101773541B1 (cg-RX-API-DMAC7.html)
CN (1) CN102753553B (cg-RX-API-DMAC7.html)
AU (1) AU2011214468B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012018904A2 (cg-RX-API-DMAC7.html)
CA (1) CA2786973C (cg-RX-API-DMAC7.html)
DK (1) DK2534149T3 (cg-RX-API-DMAC7.html)
EA (1) EA021048B1 (cg-RX-API-DMAC7.html)
ES (1) ES2525826T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20141258T1 (cg-RX-API-DMAC7.html)
IL (1) IL220845A (cg-RX-API-DMAC7.html)
ME (1) ME01926B (cg-RX-API-DMAC7.html)
MX (1) MX2012009316A (cg-RX-API-DMAC7.html)
PL (1) PL2534149T3 (cg-RX-API-DMAC7.html)
PT (1) PT2534149E (cg-RX-API-DMAC7.html)
RS (1) RS53745B1 (cg-RX-API-DMAC7.html)
SG (1) SG182471A1 (cg-RX-API-DMAC7.html)
SI (1) SI2534149T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201400196B (cg-RX-API-DMAC7.html)
WO (1) WO2011098452A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201205995B (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
AU2009323766B2 (en) 2008-12-02 2016-10-06 Wave Life Sciences Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
SG177564A1 (en) 2009-07-06 2012-02-28 Ontorii Inc Novel nucleic acid prodrugs and methods of use thereof
SI2491035T1 (sl) 2009-10-22 2017-10-30 Gilead Sciences, Inc. Derivati purina ali deazapurina uporabni za zdravljenje (med drugimi) virusnih okužb
EP2620428B1 (en) 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
SMT201800642T1 (it) * 2011-07-22 2019-01-11 Glaxosmithkline Llc Composizione
JP6246121B2 (ja) * 2012-07-13 2017-12-13 株式会社新日本科学 キラル核酸アジュバント
SG10201912895PA (en) 2012-07-13 2020-02-27 Wave Life Sciences Ltd Chiral control
JP6268157B2 (ja) 2012-07-13 2018-01-24 株式会社Wave Life Sciences Japan 不斉補助基
HK1211029A1 (en) 2012-08-24 2016-05-13 Glaxosmithkline Llc Pyrazolopyrimidine compounds
EP2922547B1 (en) 2012-11-20 2017-03-08 Glaxosmithkline LLC Novel compounds
AU2013348217B2 (en) 2012-11-20 2016-10-06 Glaxosmithkline Llc Novel compounds
SMT201700378T1 (it) 2012-11-20 2017-09-07 Glaxosmithkline Llc Nuovi composti
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
JPWO2015108047A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
EP3095460A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
PT3094728T (pt) 2014-01-16 2022-05-19 Wave Life Sciences Ltd Desenho quiral
WO2016033540A1 (en) * 2014-08-29 2016-03-03 Corium International, Inc. Microstructure array for delivery of active agents
US10584125B2 (en) * 2014-11-13 2020-03-10 Glaxosmithkline Biologicals Sa Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions
US12130267B2 (en) * 2018-11-28 2024-10-29 Shimadzu Corporation Analyzing method for azo compound
KR20250106231A (ko) 2023-12-29 2025-07-09 (주)셀트리온 안정한 약제학적 제제

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
ES2122261T3 (es) 1993-03-17 1998-12-16 Minnesota Mining & Mfg Formulacion de aerosol que contiene un adyuvante de dispersion derivado de un ester, una amida o un mercaptoester.
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
CA2310896A1 (en) 1999-07-02 2001-01-02 Japan Tobacco Inc. Hcv polymerase suitable for crystal structure analysis and method for using the enzyme
NZ514403A (en) 1999-12-27 2002-10-25 Japan Tobacco Inc Fused-ring compounds and use thereof as drugs
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US6310224B1 (en) 2001-01-19 2001-10-30 Arco Chemical Technology, L.P. Epoxidation catalyst and process
BR0206614A (pt) 2001-01-22 2004-02-17 Merck & Co Inc Composto, composição farmacêutica, método para inibir a polimerase viral de rna dependente de rna e/ou inibir a replicação viral de rna dependente de rna, método para tratar uma infecção viral de rna dependente de rna, e, uso de um composto
CA2441162A1 (en) 2001-03-19 2002-09-26 Ono Pharmaceutical Co., Ltd. Pharmaceutical composition comprising, as an active ingredient, triazaspiro[5.5]undecane derivative
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
CA2448737C (en) 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
AU2003260578A1 (en) 2002-04-04 2003-10-20 Achillion Pharmaceuticals, Inc. Hcv antiviral and cytotoxicity drug screening assay
DOP2003000641A (es) 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
AU2003276172A1 (en) 2002-10-24 2004-05-13 Glaxo Group Limited 1-acyl-pyrrolidine derivatives for the treatment of viral infections
AU2003300902A1 (en) 2002-12-13 2004-07-09 Smithkline Beecham Corporation Piperidine derivatives as CCR5 antagonists
AU2003297048A1 (en) 2002-12-13 2004-07-09 Smithkline Beecham Corporation Cyclohexyl compounds as ccr5 antagonists
DE60322423D1 (de) 2002-12-13 2008-09-04 Smithkline Beecham Corp Pyrrolidin- und azetidinverbindungen alsccr5-antagonisten
WO2004055012A1 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Indane compounds as ccr5 antagonists
AU2003296993A1 (en) 2002-12-13 2004-07-09 Smithkline Beecham Corporation Cyclopropyl compounds as ccr5 antagonists
WO2004055011A1 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Heterocyclic compounds as ccr5 antagonists
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのhcvポリメラーゼ阻害剤としての利用
EP1699512B1 (en) 2003-11-03 2012-06-20 Glaxo Group Limited A fluid dispensing device
UY28758A1 (es) 2004-02-20 2005-09-30 Boehringer Ingelheim Int Inhibidores de polimerasa viral
EP1748991A1 (en) 2004-04-28 2007-02-07 Arrow Therapeutics Limited Morpholinylanilinoquinazo- line derivatives for use as antiviral agents
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
PT1781662E (pt) 2004-08-18 2011-07-01 Pfizer Inibidores de rna polimerase dependendte de rna do vírus da hepatitie c e composições e tratamentos usando os mesmos
US20060045885A1 (en) 2004-08-27 2006-03-02 Kedl Ross M Method of eliciting an immune response against HIV
GB0423673D0 (en) 2004-10-25 2004-11-24 Glaxo Group Ltd Compounds
CN101247807A (zh) 2005-05-09 2008-08-20 艾其林医药公司 噻唑化合物及使用方法
JPWO2007034881A1 (ja) 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
GB0610666D0 (en) 2006-05-30 2006-07-05 Glaxo Group Ltd Fluid dispenser
ATE490249T1 (de) 2007-02-19 2010-12-15 Glaxosmithkline Llc Purinderivate als immunmodulatoren
DK2132209T3 (da) * 2007-03-19 2014-04-14 Astrazeneca Ab 9-substituerede 8-oxo-adeninforbindelser som modulatorer af tlr7 (toll-like receptor 7)
UY31531A1 (es) * 2007-12-17 2009-08-03 Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr)
US8777708B2 (en) 2008-06-27 2014-07-15 Microsoft Corporation Targeting control in a simulated environment
UA103195C2 (uk) * 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань

Similar Documents

Publication Publication Date Title
JP2013519645A5 (cg-RX-API-DMAC7.html)
ME01926B (me) 6-am in0-2-{[(1s)-1-meti lbuti l]oksi }-9-[5-(1-piperidinil) pentil]-7,9-di hidro-8h- purin-8-0n maleat
JP2013534248A5 (cg-RX-API-DMAC7.html)
JP2021063088A5 (cg-RX-API-DMAC7.html)
JP2013542247A5 (cg-RX-API-DMAC7.html)
JP2016534063A5 (cg-RX-API-DMAC7.html)
JP2013518107A5 (cg-RX-API-DMAC7.html)
JP2012532874A5 (cg-RX-API-DMAC7.html)
JP2009507909A5 (cg-RX-API-DMAC7.html)
JP2014521735A5 (cg-RX-API-DMAC7.html)
JP2009502743A5 (cg-RX-API-DMAC7.html)
HRP20150938T1 (hr) Derivati purina namijenjeni upotrebi u lijeäśenju alergijskih, upalnih i zaraznih bolesti
JP2017531038A5 (cg-RX-API-DMAC7.html)
JP2010077141A5 (cg-RX-API-DMAC7.html)
JP2013507415A5 (cg-RX-API-DMAC7.html)
JP2010270124A5 (cg-RX-API-DMAC7.html)
JP2014500861A5 (cg-RX-API-DMAC7.html)
JP2013509411A5 (cg-RX-API-DMAC7.html)
JP2015523546A5 (cg-RX-API-DMAC7.html)
JP2015509075A5 (cg-RX-API-DMAC7.html)
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
JP2013500977A5 (cg-RX-API-DMAC7.html)
JP2010505865A5 (cg-RX-API-DMAC7.html)
JP2011046708A5 (cg-RX-API-DMAC7.html)
JP2015508068A5 (cg-RX-API-DMAC7.html)